Prescribing of low-dose rivaroxaban in patients with atherosclerotic cardiovascular disease in the United Kingdom and the Netherlands.

Nicholas B HuntRomin PajouheshniaAllan SalihSander van DoornPatrick C SouvereinMarloes T BazelierOlaf H KlungelHelga Gardarsdottir

Published in: British journal of clinical pharmacology (2023)

There was a statistically significant increase in the use of low-dose rivaroxaban for the management of ASCVD after guideline changes in the UK and the Netherlands. There were international differences, but low-dose rivaroxaban has not been put into widespread practice.

Keyphrases

low dose
venous thromboembolism
atrial fibrillation
cardiovascular disease
pulmonary embolism
high dose
primary care
healthcare
cross sectional
type diabetes
quality improvement
coronary artery disease